Observatory to Assess the Yukon Choice PC & the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Stents Systems

Active, not recruitingOBSERVATIONAL
Enrollment

2,722

Participants

Timeline

Start Date

April 17, 2019

Primary Completion Date

April 24, 2024

Study Completion Date

May 24, 2024

Conditions
Coronaropathy
Interventions
DEVICE

Yukon Choice PC and Yukon Chrome PC

The Yukon Choice PC \& the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Coronary Stent Systems are indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease.

Trial Locations (19)

Unknown

Clinique Axium, Aix-en-Provence

Hopital A. Schweitzer - Ghca, Colmar

Centre Hospitalier de Compiègnes, Compiègne

Centre Hospitalier Sud Francilien, Corbeil-Essonnes

Clinique Louis Pasteur, Essey-lès-Nancy

GHM Grenoble, Grenoble

Centre Hospitalier Haguenau, Haguenau

Hopital privé Beauregard, Marseille

Clinique Pont de Chaume, Montauban

Hopital Privé du Confluent, Nantes

Centre Hospitalier de Périgueux, Périgueux

Centre Hospitalier de Quimper, Quimper

Clinique Saint Hilaire, Rennes

Polyclinique Saint-Laurent, Rennes

Centre Hospitalier de Soissons, Soissons

Centre Hospitalier de Saint Malo, St-Malo

Centre Hospitalier de Bigorre, Tarbes

Clinique Pasteur, Toulouse

Centre Hospitalier de Vannes, Vannes

All Listed Sponsors
collaborator

EVAMED

OTHER

lead

Translumina GmbH

INDUSTRY

NCT03918070 - Observatory to Assess the Yukon Choice PC & the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Stents Systems | Biotech Hunter | Biotech Hunter